Why Retatrutide Has No Standard Price
Unlike tirzepatide (Zepbound/Mounjaro) or semaglutide (Ozempic/Wegovy), retatrutide has no FDA-approved commercial form and no manufacturer retail price. There is no GoodRx listing, no manufacturer coupon, and no insurance formulary pathway.
All retatrutide currently available in the US comes from compounding pharmacies — either 503B outsourcing facilities (FDA-registered, batch compounders) or 503A compounding pharmacies (patient-specific prescriptions).
Estimated Cost: What Compounded Retatrutide Costs Per Month
Pricing varies by dose, pharmacy, vial size, and concentration. Verify directly with the dispensing pharmacy. The figures below reflect general market pricing as of early 2026 and are approximate.
| Weekly Dose Range | Approximate Monthly Cost |
|---|---|
| 0.5–2 mg/week | $100–$200/month |
| 2–4 mg/week | $150–$300/month |
| 4–8 mg/week | $250–$450/month |
| 8–12 mg/week | $400–$700/month |
Approximate figures based on general market pricing. Verify with your specific pharmacy.
Why Insurance Doesn't Cover Retatrutide
Insurance coverage for a drug requires FDA approval for the specific indication. As of April 2026, retatrutide has not received New Drug Application (NDA) approval and has no commercially manufactured form. Even when/if approved, formulary inclusion typically follows 1–2 years later.
Where to Get Retatrutide Legally
Retatrutide requires a valid prescription from a licensed clinician. Legitimate options:
- Telehealth weight management platforms — many now list retatrutide explicitly and can prescribe and arrange dispensing within most US states
- 503A compounding pharmacies — traditional pharmacies that compound patient-specific prescriptions
- In-person obesity medicine or bariatric medicine clinics — brick-and-mortar practices with compounding relationships
Do not buy retatrutide from international online sources, unverified online marketplaces, or "research chemical" suppliers. These are not regulated — doses and sterility are unverified — and use carries serious legal and safety risk.
Cost Comparison: Retatrutide vs Tirzepatide vs Semaglutide
| Drug | Form | Insurance | Approx. Patient Cost |
|---|---|---|---|
| Semaglutide (Wegovy) | FDA-approved commercial | Yes (if covered) | $0–$1,350+/mo |
| Tirzepatide (Zepbound) | FDA-approved commercial | Yes (if covered) | $0–$1,060+/mo |
| Retatrutide | Compounded only | None | $150–$700/mo |
For patients without insurance coverage, compounded retatrutide can be meaningfully less expensive than brand-name alternatives. The trade-off is being at an earlier stage of the clinical evidence trajectory.